This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F60461373%3A22340%2F10%3A00023479%21RIV11-MSM-22340___/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F60461373%3A22340%2F10%3A00023479%21RIV11-MSM-22340___
rdf:type
skos:Concept n13:Vysledek
dcterms:description
Objectives: The receptor for advanced glycation end-products (RAGE) takes part in the pathogenesis ofmany diseases, including diabetes mellitus and cancer. AGE-precursors are detoxified by glyoxalase (GLO).sRAGE, soluble RAGE, is an inhibitor of pathological effects mediated via RAGE. The aim was to study sRAGE and polymorphisms of RAGE (AGER) and GLO genes in patients with pancreas cancer (PC). Design and Methods: The studied group consisted of 51 patients with PC (34 with impaired glucose tolerance?IGT, 17without IGT), 34 type 2DMand 154 controls. For genetic analysis, the number of patients was increased to 170. Serum sRAGE was measured by ELISA and all polymorphisms (RAGE -429T/C, -374T/A, 2184A/G, Gly82Ser and GLO A419C) were determined by PCR-RFLP and confirmed by sequencing. Results: Soluble RAGE is decreased in patientswith PC compared to atients with DM and controls (975?532 vs. 1416?868 vs. 1723?643 pg/mL, p< 0.001). Patients with PC and IGT have lower sRAGE levels compared to pati Objectives: The receptor for advanced glycation end-products (RAGE) takes part in the pathogenesis ofmany diseases, including diabetes mellitus and cancer. AGE-precursors are detoxified by glyoxalase (GLO).sRAGE, soluble RAGE, is an inhibitor of pathological effects mediated via RAGE. The aim was to study sRAGE and polymorphisms of RAGE (AGER) and GLO genes in patients with pancreas cancer (PC). Design and Methods: The studied group consisted of 51 patients with PC (34 with impaired glucose tolerance?IGT, 17without IGT), 34 type 2DMand 154 controls. For genetic analysis, the number of patients was increased to 170. Serum sRAGE was measured by ELISA and all polymorphisms (RAGE -429T/C, -374T/A, 2184A/G, Gly82Ser and GLO A419C) were determined by PCR-RFLP and confirmed by sequencing. Results: Soluble RAGE is decreased in patientswith PC compared to atients with DM and controls (975?532 vs. 1416?868 vs. 1723?643 pg/mL, p< 0.001). Patients with PC and IGT have lower sRAGE levels compared to pati
dcterms:title
Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer
skos:prefLabel
Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer
skos:notation
RIV/60461373:22340/10:00023479!RIV11-MSM-22340___
n3:aktivita
n18:I n18:S n18:P
n3:aktivity
I, P(NR9528), S
n3:cisloPeriodika
10-11
n3:dodaniDat
n5:2011
n3:domaciTvurceVysledku
n15:2901153
n3:druhVysledku
n7:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n12:predkladatel
n3:idSjednocenehoVysledku
288523
n3:idVysledku
RIV/60461373:22340/10:00023479
n3:jazykVysledku
n10:eng
n3:klicovaSlova
Cancer; Diabetes mellitus; Glyoxalase; Pancreas; Polymorphism; RAGE; Receptor for advanced glycation end products; Soluble receptor for advanced glycation end products sRAGE
n3:klicoveSlovo
n4:Cancer n4:Diabetes%20mellitus n4:Receptor%20for%20advanced%20glycation%20end%20products n4:RAGE n4:Soluble%20receptor%20for%20advanced%20glycation%20end%20products%20sRAGE n4:Glyoxalase n4:Pancreas n4:Polymorphism
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[E4D5A0431D85]
n3:nazevZdroje
Clinical Biochemistry
n3:obor
n14:CB
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
6
n3:projekt
n11:NR9528
n3:rokUplatneniVysledku
n5:2010
n3:svazekPeriodika
43
n3:tvurceVysledku
Zima, T. Jáchymová, M. Krechler, T. Mestek, Oto Žák, A. Kalousová, M.
n3:wos
000279133100015
s:issn
0009-9120
s:numberOfPages
5
n16:organizacniJednotka
22340